Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.

This trial is testing a combination of three drugs — famitinib (blocks tumor blood vessel growth), camrelizumab (an immunotherapy), and standard chemotherapy — as a first-line treatment for triple-negative breast cancer (TNBC) that is locally advanced or has spread to other parts of the body. TNBC is an aggressive form of breast cancer that lacks the three common receptors. **You may be eligible if...** - You have triple-negative breast cancer (no HER2, estrogen, or progesterone receptors) confirmed by biopsy - Your cancer is locally advanced or metastatic - You have not had previous chemotherapy or targeted therapy for this stage of disease - Your overall health is good (ECOG 0–1) with a life expectancy of at least 3 months **You may NOT be eligible if...** - You have already received chemotherapy or targeted therapy for metastatic/advanced disease - You have active autoimmune disease or serious infections - You have significant heart, liver, or kidney problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.